Allergy & Immunology | Page 8 of 36 | Links Medicus Content Curation & Alerts in Medicine

[Preprint] Serological responses to COVID-19 booster vaccine in England.

26 Nov, 2021 | 08:34h | UTC

Serological responses to COVID-19 booster vaccine in England – medRxiv

Commentary from the author on Twitter (thread – click for more)

1/ Our preprint on #SARSCoV2 antibody responses in UK adults receiving a #COVID19 vaccine booster with the Pfizer vaccine at least 6 months after primary immunisation with Pfizer or AZ vaccine, which was given at an extended interval (8-12 wks) … ?

? https://t.co/JYxwH4JM51

— Shamez Ladhani (@ShamezLadhani) November 25, 2021

A population-based cohort study in Qatar showed reinfections had 90% lower odds of resulting in hospitalization or death than primary infections.

25 Nov, 2021 | 10:46h | UTC

Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections – New England Journal of Medicine

AAP Clinical Report: Biologics for Asthma and Allergic Skin Diseases in Children.

19 Nov, 2021 | 10:34h | UTC

Biologics for Asthma and Allergic Skin Diseases in Children – Pediatrics

Phase 4 RCT: Concomitant administration of COVID-19 vaccines (AstraZeneca or Pfizer) with seasonal influenza vaccines in adults is safe and preserves antibody responses to both vaccines.

14 Nov, 2021 | 20:14h | UTC

Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial – The Lancet

Opinion | Protective immunity after recovery from SARS-CoV-2 infection.

10 Nov, 2021 | 07:15h | UTC

Protective immunity after recovery from SARS-CoV-2 infection – The Lancet Infectious Diseases

Commentary on Twitter

"Policy makers should consider recovery from previous SARS-CoV-2 infection equal to immunity from vaccination for purposes related to entry to public events, businesses, and the workplace,or travel requirements"
Do you agree with this?
I don't #IDtwitter https://t.co/FHbgXILD8Z

— Antibiotic Stewa®️x? Bassam Ghanem (@ABsteward) November 9, 2021

How protein-based COVID vaccines could change the pandemic.

9 Nov, 2021 | 01:41h | UTC

How protein-based COVID vaccines could change the pandemic – Nature

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines.

9 Nov, 2021 | 01:31h | UTC

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines – The Conversation

Study compares the decline in effectiveness for Moderna, Pfizer, and Janssen vaccines and consequences for mortality.

5 Nov, 2021 | 09:59h | UTC

Original study: SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 – Science

News release: Breakthrough Infection Study Compares Decline in Vaccine Effectiveness and Consequences for Mortality – Public Health Institute

Commentary on Twitter

A new study of more than 780,000 United States Veterans shows that, although vaccination remains protective against #SARSCoV2 infection, protection waned as the Delta variant emerged in America.

Read more: https://t.co/8qRlKE107H #ScienceResearch pic.twitter.com/XmDQ7frIlT

— Science Magazine (@ScienceMagazine) November 4, 2021

CDC Guidance: Immunocompromised may need a fourth Covid-19 shot.

4 Nov, 2021 | 10:06h | UTC

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States – Centers for Disease Control and Prevention

Commentaries:

Immunocompromised may need a fourth Covid-19 shot, CDC says – CNN

Some immunocompromised people can receive a 4th Covid shot, CDC says – NBC News

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

4 Nov, 2021 | 10:00h | UTC

Ten Things to Know About MIS-C – American College of Cardiology

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

M-A: Zinc might help to stave off respiratory infection symptoms and cut illness duration – “But quality of evidence variable, and no clarity on optimal formulation or dose”.

4 Nov, 2021 | 09:53h | UTC

News Release: Zinc might help to stave off respiratory infection symptoms and cut illness duration – BMJ

Original Study: Zinc for the prevention or treatment of acute viral respiratory tract infections in adults: a rapid systematic review and meta-analysis of randomised controlled trials – BMJ Open

Commentary on Twitter

A zinc supplement might help stave off the symptoms of respiratory tract infections, such as coughing, congestion, and sore throat, and cut illness duration, suggests a pooled analysis of the available evidence, published in @BMJ_Open https://t.co/Nq5KadAw5y

— BMJ (@bmj_company) November 2, 2021

In Covid-19 vaccinated people, those with prior infection are likely to have more antibodies.

2 Nov, 2021 | 03:03h | UTC

News release: In Covid-19 Vaccinated People, Those with Prior Infection Likely to Have More Antibodies – Johns Hopkins Medicine

Original Article: Durability of Antibody Levels After Vaccination With mRNA SARS-CoV-2 Vaccine in Individuals With or Without Prior Infection – JAMA

CDC Study: COVID-19 vaccine associated with 5 times the protection of ‘natural immunity’.

31 Oct, 2021 | 20:09h | UTC

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19–Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity — Nine States, January–September 2021 – CDC Morbidity and Mortality Weekly Report

Commentaries:

COVID-19 vaccine gives 5 times the protection of ‘natural immunity,’ data show – CIDRAP

COVID shots more protective than past infection, study shows – Associated Press

Commentary on Twitter

⚠️BREAKING—REINFECTION & NATURAL IMMUNITY—new CDC study in hospitalized adults finds: unvaccinated people with prior #COVID19 infection recently were **5 times more likely** to be reinfected / get breakthrough versus people recently fully vaccinated! ? https://t.co/VGmWPmm5lE pic.twitter.com/mlt5fJ3643

— Eric Feigl-Ding (@DrEricDing) October 29, 2021

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.

29 Oct, 2021 | 10:16h | UTC

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern – Science

Commentary from the author on Twitter (thread – click for more)

Antibodies come and go, but memory cells are forever (maybe not forever, but at least 6 months). Our latest in @ScienceMagazine: https://t.co/YHHBMrMsTA

How long does immune memory last after #mRNA vax? Is it effective vs. variants? What about “boosted” responses?

Full ?⬇️… pic.twitter.com/oZ5BxLuVdw

— Rishi Goel (@rishirajgoel) October 14, 2021

Breakthrough infections occur in those with lower antibody levels.

27 Oct, 2021 | 01:45h | UTC

Breakthrough Infections Occur in Those with Lower Antibody Levels, Israeli Study Shows – NIH Director’s Blog

Original study: Covid-19 Breakthrough Infections in Vaccinated Health Care Workers – New England Journal of Medicine

Mix-and-match COVID vaccines ace the effectiveness test – “No need for brand loyalty”.

27 Oct, 2021 | 01:42h | UTC

Mix-and-match COVID vaccines ace the effectiveness test – Nature

Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.

Should You Mix and Match Your Booster Shot?

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

Heterologous AstraZeneca/Pfizer vaccination seems to be associated with increased effectiveness against Covid-19 compared to homologous Pfizer/Pfizer vaccination.

27 Oct, 2021 | 01:44h | UTC

Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination – Nature

Should You Mix and Match Your Booster Shot?

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

Commentary on Twitter

A dose of the AstraZeneca COVID-19 vaccine followed by a dose of the Pfizer/BioNTech vaccine confers better protection against SARS-CoV-2 infection than two doses of the Pfizer vaccine, according to a study in healthcare workers published in @Nature. https://t.co/6hIVkiOLQ1 pic.twitter.com/AmsyVUMpoj

— Nature Portfolio (@NaturePortfolio) October 26, 2021

COVID super-immunity: one of the pandemic’s great puzzles – “People who have previously recovered from COVID-19 have a stronger immune response after being vaccinated than those who have never been infected. Scientists are trying to find out why”.

27 Oct, 2021 | 01:41h | UTC

COVID super-immunity: one of the pandemic’s great puzzles – Nature

Review: Thoracic involvement and imaging patterns in IgG4-related disease.

26 Oct, 2021 | 01:22h | UTC

Thoracic involvement and imaging patterns in IgG4-related disease – European Respiratory Review

Commentary on Twitter

Thoracic and lung involvement of IgG4-RD are heterogeneous and underevaluated. Peribronchovascular involvement and lymph node enlargement are most frequent patterns. Interstitial disease pattern seems to be associated with lower rate of treatment response. https://t.co/AMuLjPByut pic.twitter.com/ZmDrz6nK6g

— ERS publications (@ERSpublications) October 13, 2021

Review: Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?

25 Oct, 2021 | 00:03h | UTC

Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? – The Lancet Respiratory Medicine

Commentary on Twitter

New on our #COVID19 resource centre—Personal View: Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?

Read in @LancetRespirMed: https://t.co/ZOTgVQYd6w pic.twitter.com/7BwRPLzsib

— The Lancet (@TheLancet) October 23, 2021

Perspective | The flawed science of antibody testing for SARS-CoV-2 immunity.

22 Oct, 2021 | 10:30h | UTC

The Flawed Science of Antibody Testing for SARS-CoV-2 Immunity – JAMA

FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK.

21 Oct, 2021 | 10:09h | UTC

FDA authorizes booster doses of Moderna and Johnson & Johnson vaccines, says mix and match OK – CNN

Cohort Study: The effectiveness of heterologous AstraZeneca (AZ)/mRNA prime-boost vaccination was more significant (68%) compared to the effectiveness of homologous AZ/AZ vaccination (50%) against symptomatic Covid-19 infection in Sweden.

20 Oct, 2021 | 10:27h | UTC

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study – The Lancet Regional Health Europe

Commentary: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

Commentary on Twitter

Study from Sweden assessing heterogenous vaccination in 3,445,061 individuals who received AZ as the first dose and either #pfizer, #moderna, or #AZ as second dose showed the following vaccine effectiveness:

AZ/Pfizer- 67%
AZ/Moderna- 79%
AZ/AZ- 50%https://t.co/UN0pey2kJ2

— Yan Leyfman, MD (@YLeyfman) October 19, 2021